Global Psoriasis Drugs Industry Market Overview, Cost Structure Analysis, Growth Opportunities and Forecast to 2027 – 3rd Watch News

With having published myriads of reports, Psoriasis Drugs Market Research imparts its stalwartness to clients existing all over the globe. Our dedicated team of experts delivers reports with accurate data extracted from trusted sources. We ride the wave of digitalization facilitate clients with the changing trends in various industries, regions and consumers. As customer satisfaction is our top priority, our analysts are available to provide custom-made business solutions to the clients.

In this new business intelligence report, Psoriasis Drugs Market Research serves a bunch of market forecast, structure, potential, and socioeconomic impacts associated with the global Psoriasis Drugs market. With Porters Five Forces and DROT analyses, the research study incorporates a comprehensive evaluation of the positive and negative factors, as well as the opportunities regarding the Psoriasis Drugs market.

Get Free sample copy of this report, @https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-psoriasis-drugs-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/148089#request_sample

The Psoriasis Drugs market report has been fragmented into important regions that showcase worthwhile growth to the vendors. Each geographic segment has been measured based on supply-demand status, distribution, and pricing. Further, the study brings information about the local distributors with which the market players could create collaborations in a bid to sustain production footprint.

The following manufacturers are covered:

Takeda PharmaceuticalJanssen BiotechMerckUCBBiogenAbbvieCelgene CorporationEli Lilly & CompanyAmgenAbbVieJohnson & JohnsonAstraZenecaNovartis AGStiefel LaboratoriesPfizer

Segment by Regions

North America

Europe

China

Japan

Southeast Asia

India

Market Segmentation based on Type:

Tumor Necrosis Factor InhibitorInterleukin InhibitorsOthers

Market Segmentation based on Application:

Plaque PsoriasisGuttate PsoriasisInverse PsoriasisPustular PsoriasisErythrodermic Psoriasis

Get Your Copy at a Discounted Rate!!!

Ask For Discount https://www.globalmarketers.biz/discount_inquiry/discount/148089

Segmentation of the Psoriasis Drugs market to target the growth outlook and trends affecting these segments.

Make An Enquiry About This Report @What does the Psoriasis Drugs market report contain?

https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-psoriasis-drugs-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/148089#inquiry_before_buying

Readers can get the answers of the following questions while going through the Psoriasis Drugs market report:

Browse the complete report @https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-psoriasis-drugs-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/148089#table_of_contents

See the original post here:

Global Psoriasis Drugs Industry Market Overview, Cost Structure Analysis, Growth Opportunities and Forecast to 2027 - 3rd Watch News

Psoriasis Treatment Market Presents an Overall Analysis, Trends and Forecast to 2025 – 3rd Watch News

Global Psoriasis Treatment Industry Market, 2020-2025 Research Report provides crucial statistics on the market status of the Global Psoriasis Treatment Industry manufacturers and is a respected source of guidance and direction for companies and individuals interested in the industry.

This Psoriasis Treatment Industry market research study is a collection of insights that translate into a gist of this industry. It is explained in terms of a plethora of factors, some of which include the present scenario of this marketplace in tandem with the industry scenario over the forecast timeframe.

Request a sample Report of Psoriasis Treatment Industry Market at:https://www.marketstudyreport.com/request-a-sample/2728907

The report is also inclusive of some of the major development trends that characterize the Psoriasis Treatment Industry market. A comprehensive document in itself, the Psoriasis Treatment Industry market research study also contains numerous other pointers such as the current industry policies in conjunction with the topographical industry layout characteristics. Also, the Psoriasis Treatment Industry market study is comprised of parameters such as the impact of the current market scenario on investors.

The pros and cons of the enterprise products, a detailed scientific analysis pertaining to the raw material as well as industry downstream buyers, in conjunction with a gist of the enterprise competition trends are some of the other aspects included in this report.

How has the competitive landscape of this industry been categorized?

Regional landscape: How will the details provided in the report help prominent stakeholders?

Ask for Discount on Psoriasis Treatment Industry Market Report at:https://www.marketstudyreport.com/check-for-discount/2728907

Other pivotal aspects encompassed in the Psoriasis Treatment Industry market study:

For More Details On this Report: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-psoriasis-treatment-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Related Reports:

1. COVID-19 Outbreak-Global Transplant Diagnostic Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020Read More: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-transplant-diagnostic-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

2. COVID-19 Outbreak-Global Cloud Kitchen Foodservice Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020Read More: https://www.marketstudyreport.com/reports/covid-19-outbreak-global-cloud-kitchen-foodservice-industry-market-report-development-trends-threats-opportunities-and-competitive-landscape-in-2020

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Read more:

Psoriasis Treatment Market Presents an Overall Analysis, Trends and Forecast to 2025 - 3rd Watch News

UCB flashes the data behind its positive psoriasis readouts. Can it compete in a crowded field? – Endpoints News

Eight months after UCB announced that a little-watched drug candidate outperformed J&Js blockbuster Stelara, the Belgian pharma is out with full data that one investigator calls remarkable.

In the Phase III trial, 58.6% of patients who took UCBs IL-17 blocker bimekizumab were completely cleared of skin lesions after 16 weeks, compared to 20.9% of patients on Stelara. The UCB drug also outperformed Stelara at how many patients were clear after one year and at lesser benchmarks for plaque clearance, with more than 8 out of 10 patients showing 90% improvement, compared to roughly half on Stelara.

In a second study, first announced positive in November, bimekizumab was compared to placebo. In that one, 68% of patients on the treatment arm saw their skin completely clear and over 90% saw a 90% improvement. For placebo that number was 1.2%.

It really showed some quite impressive, remarkable I dont know how you want to say it, but extremely high level of responses, Kenneth Gordon, lead investigator on the placebo-controlled study, told Endpoints News.

Gordon singled out a couple distinct characteristics about the responses that stood out. Those included how sweepingly the drug alleviated symptoms, how quick it did so, and how long it lasted.

If you compare it to other clinical trials programs, both the speed and magnitude of the responses were around the highest weve seen, Gordon said.

Researchers often caution against comparing different clinical trials, such comparisons will be crucial for a drug like bimekizumab. The plaque psoriasis is a highly competitive market, suffuse with approved biologics from some of the worlds biggest drugmakers. Stelara is just one of several options patients can currently choose from.

The new data were released in abstracts for the annual American Academy of Dermatology meeting. On Friday afternoon, AbbVie also released abstracts from its open-label Phase III trial testing Skyrizi, an IL-23 inhibitor approved last year for psoriasis, against Novartis Cosentyx.

While trouncing Cosentyx, Skyrizi showed a virtually identical ability as UCBs drug to clear plaque psoriasis after one year: 66%. In addition, Eli Lillys IL-17 inhibitor beat J&J Tremfya last year in a head to head trial on psoriasis. UCB also beat AbbVies Humira last year, although results have yet to be announced.

From a medical perspective, though, Gordon suggested that asking which one is best might not be the best approach. Instead, prescribing decisions may come down to matching individual patients to the best drug.

Bimekizumab blocks multiple cytokines involved in plaque psoriasis, IL-17a and IL-17f. Because IL-17f exists in greater quantities in plaques, but IL-17a is more active, it had been an open question whether it was best to blockade both or if you could just target one and have the same effect.

Though cautioning no trial has been completed, Gordon said the latest data seem to resolve that debate. He argued the new insight, along with some of the other new molecules, represented a capstone on the progress the field has made since the chemotherapy drug methotrexate was first given to modest effect in the 1950s.

This might be culminating biologic molecule for psoriasis we have in the near future, he said. Now the question is how can we best apply each of our medications.

Read this article:

UCB flashes the data behind its positive psoriasis readouts. Can it compete in a crowded field? - Endpoints News

U.S. Dermatology Partners Georgetown, formerly Georgetown Dermatology & Skin Cancer Center, is pleased to announce the addition of David Ettinger,…

Dermatology PA, David Ettinger joins U.S. Dermatology Partners Georgetown

GEORGETOWN, Texas (PRWEB) June 22, 2020

U.S. Dermatology Partners Georgetown is excited to welcome David Ettinger, PA-C. Born and raised in the state of Washington, David relocated after high school and has lived in California, Arizona, and South America. He attended Northern Arizona University to obtain his Bachelor of Science before earning his Master of Physician Assistant Studies at the University of Washington School of Medicine in Seattle.

Since graduating, David Ettinger has worked in dermatology and craniofacial reconstructive plastic surgery with a focus in pediatrics. He loves dermatology and helping others feel more comfortable in their skin and providing relief to those struggling with various skin conditions.

He has participated in clinical research trials for psoriasis and "Spray-on Skin" to determine their efficacy and safety in the pediatric population. "It has been wonderful to be part of the process to find new ways to treat and provide relief to those suffering", says David, a member of the Society of Dermatology Physician Assistants (SDPA).

As a physician assistant with several years of dermatology experience, David will treat patients with medical dermatology concerns such as acne treatment, psoriasis, rosacea, and eczema. He welcomes both adult and pediatric patients at our Georgetown, Texas dermatology clinic.

David Ettinger feels lucky to be raising 3 energetic, loving children alongside his wife. They enjoy spending time on the lake, exercising, and watching their children participate in their weekend sporting events.

U.S. Dermatology Partners Georgetown has been serving the dermatology needs of Georgetown and the Central Texas community since 2003. Founded by Dr. Kevin Miller, the Georgetown dermatology group includes Board-Certified Dermatologists, Dr. Monica Madray, Dr. Elizabeth Morris, Dr. Weilan Johnson, Fellowship-Trained Mohs Surgeon, Dr. Nicholas Snavely, Certified Physician Assistant David Ettinger, PA-C, and Licensed Aesthetician Corey Stoever, LA.

The state-of-the-art dermatology office was expanded in 2011 to meet the growing patient demand. U.S. Dermatology Partners Georgetown offers a full suite of clinical and surgical services, including Mohs surgery for the treatment of skin cancer. The providers treat conditions like acne, psoriasis and eczema to relieve or improve symptoms that limit your comfort, health and enjoyment. We provide specialized, highly effective treatments for a variety of skin cancers to restore and extend the quality of your life. The providers, who are parents of young children, feel comfortable treating patients of all ages, from the very young to the retirees of the Sun City community.

For more information or to schedule a new appointment, please contact the office at (512) 819-9910.

About U.S. Dermatology Partners

As one of the largest physician-owned dermatology practices in the country, U.S. Dermatology Partners' patients not only have access to general medical, surgical, and cosmetic skin treatments through its coordinated care network, but also benefit from the practice's strong dermatology subspecialty thought leaders and medical advisory board. To be the best partners to its patients, U.S. Dermatology Partners is fervently focused on providing the highest level of patient-first care, and its team, therefore, includes recognized national leaders in areas such as clinical research, psoriasis, and Mohs Surgery. To learn more, visit usdermatologypartners.com.

For the original version on PRWeb visit: https://www.prweb.com/releases/u_s_dermatology_partners_georgetown_formerly_georgetown_dermatology_skin_cancer_center_is_pleased_to_announce_the_addition_of_david_ettinger_pa_c_june_22nd/prweb17207222.htm

Read more here:

U.S. Dermatology Partners Georgetown, formerly Georgetown Dermatology & Skin Cancer Center, is pleased to announce the addition of David Ettinger,...

Melanoma Risk and Biologic Therapy: Is There a Link? – Cancer Therapy Advisor

Immune-mediated inflammatory conditions such as inflammatory bowel disease (Crohn disease [CD], ulcerative colitis [UC]), psoriasis, and rheumatoid arthritis (RA) are frequently treated with antitumor necrosis factor-alpha (TNF-) agents. TNF- inhibitors (TNFIs) have shown significant clinical safety and efficacy profiles in these inflammatory conditions; however, the potential risks of long-term use are a consistent concern of both physicians and patients.

As the TNF- pathway plays a critical role in tumor surveillance, there is concern that inhibition of this pathway could predispose patients to certain malignancies.1 One such cancer that is of great concern with respect to the TNF- pathway is melanoma.1 As the use of TNFIs and other biologics have grown increasingly popular, there has been noteworthy research interest in the actual risk of melanoma in these patients.

When evaluating a study estimating the risk of melanoma in patients receiving TNFIs, it is critical to determine if the comparison group is either the general population or patients with inflammatory conditions treated with other systemic therapy. There is a meager number of studies specifically evaluating the latter, especially studies with IBD and psoriasis. Interestingly, Esse and colleagues recently published a systematic review and meta-analysis in JAMA Dermatology specifically evaluating the risk of melanoma in patients with IBD, RA, and psoriasis who were treated with biologic therapy compared to those who had received only other conventional systemic therapy.2

The authors identified 7 studies, all of which were published between 2007 and 2019, and were cohort studies that were conducted in several countries (United States, Denmark, Sweden, and Australia). These studies included a total of 34,029 patients who received biologic therapy compared with 135,370 biologic-naive patients who had received conventional systemic therapy. Mean patient-follow duration ranged from 1 year to 5.48 years. Most studies included TNFIs, however, there were some patients receiving abatacept and rituximab were also included in the meta-analysis.

There were no significant differences found in the pooled relative risk (pRR) estimates for patients treated with biologic therapy compared with those who were treated with conventional therapy in IBD (pRR, 1.20; 95% CI, 0.60-2.40) and RA (pRR, 1.20; 95% CI, 0.83-1.74).

All of the included studies were considered high-quality studies, according to the review authors, and there was no evidence of publication bias or significant heterogeneity in the studies across the patient groups. When specifically looking at each biologic agent individually (TNFIs, abatacept, rituximab), there remained no statistically significant difference in melanoma risk when compared with patients receiving conventional therapy. If individual RA studies were excluded, sensitivity analyses showed that the pRR continued to not be statistically significant from patients receiving conventional therapy.

A key distinguishing factor of this study was inclusion of patients with inflammatory conditions whom were biologic naive and their comparison with those receiving standard therapies. This study is interesting to juxtapose with several prior studies evaluating similar melanoma outcomes. Singh and colleagues published a similar systemic review and meta-analysis in Clinical Gastroenterology and Hepatology in 2014 that specifically evaluated the risk of melanoma in patients with IBD.3 This review evaluated 12 studies that included 172,837 patients with IBD and found a pooled crude incidence rate (IR) of melanoma in patients with IBD of 27.5 cases per 100,000 person-years (95% CI, 19.9-37). Overall, IBD was associated with a 37% increased risk of melanoma. This relative risk was higher in those patients with CD (RR, 1.80; 95% CI, 1.17-2.75) compared with those with UC (RR, 1.23; 95% CI, 1.01-1.50). This increased risk of melanoma was found to be independent of biologic therapy.

Another systematic review published by Peleva and colleagues in the British Journal of Dermatology in 2018 evaluated 8 prospective cohort studies evaluating the risk of all cancers in patients with psoriasis who were treated with biologic therapies.4 The authors found an increase in nonmelanoma skin cancer (NMSC) particularly squamous cell carcinoma but there was no evidence of increased risk of melanoma. This review was limited by the inclusion of only 1 study evaluating melanoma risk in patients treated with ustekinumab.

Read more from the original source:

Melanoma Risk and Biologic Therapy: Is There a Link? - Cancer Therapy Advisor

Skin Picking: How to Manage and Treat the Stress Disorder – Coveteur

How to address excoriation disorder during extreme stress.

I thought the office was empty, but it wasnt. I turned a corner and found a lone coworker with an embarrassed look on his face. He, too, thought he was alone, so hed picked at a pimple on his face, which was now bleeding. I felt his pain, since at the time I was suffering from the worst bout of adult acne Id ever had. My one reprieve was going to the office each day, where I had no choice but to keep my hands off my face.

After countless workers began working from home this spring, my friends have gradually revealed that theyre all struggling with the same issuethey cant stop picking at their faces. And who can really blame them? Tensions are high, to say the least, and recent events are triggering more cortisol (your fight-or-flight hormone) to flood our systems and incite stress responses, like excoriation disorder.

Also known as chronic skin picking or dermatillomania, excoriation disorder is related to obsessive-compulsive disorder and involves repeatedly picking at the skin, which can cause painful lesions as well as a disruption to daily life. Not all forms of skin picking fall into this more serious categoryin fact, most dontbut expert insight into both the causes and healing process can help anyone compulsively picking at their skin, hair, nails, or scabs begin to move forward on the path to recovery.

Advertisement

Stress, stress, and more stress. Dr. Nancy Irwin, a licensed clinical psychologist, confirmed that the immense amount of stress and anxiety many people are experiencing right now are playing a two-pronged rolethey can both cause acne to develop and drive the desire to pick. Dr. Irwin noted that stress is behind about 72 percent of all illnesses and conditions, skin related or not. As the skin is our largest organ, it can hold clues as to what the person is feeling about the self and/or life at the current time, Dr. Irwin explains. The negative effects of stress on skin can manifest in conditions like acne, dandruff, itchy skin, and even hair loss. Stress can also cause flare-ups of skin issues such as psoriasis and rosacea to occur.

She notes that skin picking can become a compulsion if you do not identify the root of the problem, as well as make lifestyle changes that help you better manage your stress levels. Having a positive support system and making time for fun and self-care are a good place to start. These can involve exercising and eating healthy, enjoying leisure activities, or practicing your faith or meditation. We all have varying degrees of stress and challenges, so Dr. Irwin encourages patients to have a go-to list of how you can self-soothe and process those stressors when they present themselves. Work on building up trust in yourself that you have everything you need to weather the current challenges.

We know that picking at acne lesions, dry skin, or any part of our bodies can damage the skin, resulting in hyperpigmentation, multiple forms of scarring, disfigurement from lesions, and open wounds that might lead to further infection. Stopping the impulse to do so is easier said than done, however. Everything has a positive intent, and picking is a relief of anxiety, Dr. Irwin clarifies. But that doesn't mean its a healthy coping mechanism, [Patients that pick] are avoiding the issue [causing their stress] and compounding the belief that there is no other way to manage the pain or issue at hand.

One tactic for managing the urge to pick that Dr. Irwin recommends is asking yourself empowering questions likeIf I were able to handle this stress in my life while respecting my body, how would I do so? Who do I know that can help me? Another is seeking the counsel of those who have overcome picking-related struggles, such as in a support group. You are not alone. There are millions of others who have suffered this and overcome it. They can be excellent resources for you. If you are looking for professional help, Dr. Irwin suggests working with a therapist who concentrates in this area.

Advertisement

Skin-picking disorder impacts as many as one in twenty people, with women being more commonly affected than men. After you identify the source of your stress and anxiety and seek treatment, the next step is healing the preexisting damage. Dr. Annie Chiu, board-certified cosmetic and general dermatologist, concedes that right now is an especially hard time to stop picking at your skin. She explains that stress weakens our skin barrier, which is why most skin conditions (like acne and psoriasis) tend to flare up during those moments. More lesions means you have more opportunities to pick. When you have good skin, its just not as tempting, she notes.

Weve all tried to pop the occasional pimple that we should have left alone, and watched it heal slower as a result, but serious cases of excoriation disorder can lead to more serious damage, like tissue injury, scarring, and discoloration. To heal the physical effects of picking or more extreme cases of excoriation disorder, Dr. Chiu recommends using a gentle facial cleanser followed by a soothing balm or serum to maintain skin hydration. She suggests reaching for any occlusive protectant (aka slippery balm-type products) like Aquaphor to help skin cells heal faster and create a protectant barrier. Look for ingredients such as ceramides, niacinamide, or hyaluronic acid, all of which can help build skin-health barriers. She also recommends incorporating overnight moisturizing masks and sheet masks into your skin-care routinebut be sure not to go overboard on new products, as tempting as it can be to try everything under the sun.

To address the breakouts themselves, Dr. Chiu is a fan of acne patches to cover the zit, such as COSRX Acne Pimple Master Patch, which physically blocks you from picking and contains acne-fighting ingredients like tea tree oil and salicylic acid. Says Dr. Chiu, If were actively conscious were taking care of our skin, we are not going to be as prone to want to ruin that. For those looking to heal deeper scarring, there are also in-office solutions such as cortisone injections and laser treatments. Your dermatologist will be able to recommend the best course of action depending on your current skin condition.

Below, five of our favorite products to help heal breakouts, soothe the skin, and repair damage from previous picking.

Read the rest here:

Skin Picking: How to Manage and Treat the Stress Disorder - Coveteur

Are Patients With Psoriasis at Increased Risk for Serious Infection, Hospitalization? – Dermatology Advisor

Psoriasis is associated with increased risk for serious infection, according to the results of cohort study data published in the British Journal of Dermatology. During 5 years of follow-up, patients with psoriasis were more often hospitalized for infections than individuals without psoriasis.

Investigators conducted a cohort study of adults (18 years) with and without psoriasis using the United Kingdom Clinical Practice Research Datalink (CPRD). CPRD data were linked to hospital and mortality records in the United Kingdom for the years 2003 to 2016. Patients with psoriasis were matched with up to 6 control patients by age, sex, and place of clinical care. History of hospitalization was ascertained from the Hospital Episode Statistics database; death was ascertained from Office of National Statistics mortality records. Stratified Cox proportional hazard models were used to examine the relationship between psoriasis, hospitalization, and mortality. Models were adjusted for age, economic deprivation, body mass index, alcohol intake, smoking status, and comorbid conditions.

The study cohort comprised 69,312 patients with psoriasis and 338,598 comparators. Patients and comparators were followed for a median (interquartile range) of 4.9 (5.9) and 5.1 (6.3) years, respectively. The incidence rate of serious infection was 20.5 per 1000 person-years (95% confidence interval [CI], 20.0-21.0) in patients with psoriasis and 16.1 per 1000 person-years (95% CI, 15.9-16.3) in comparators. The fully adjusted hazard ratio (HR) for hospitalizations due to infection was 1.36 (95% CI, 1.31-1.40) in patients with psoriasis vs comparators. When analyses were stratified by infection type, patients with psoriasis had the highest HR for skin and soft-tissue infections (HR, 1.56; 95% CI, 1.43-1.70). Risk for respiratory infections was also increased (HR, 1.35; 95% CI, 1.27-1.44). Death due to any infection was also more common in patients vs control patients (HR, 1.33; 95% CI, 1.08-1.63).

Although the absolute risk for serious infection in patients with psoriasis was small, the likelihood of hospitalization and death were nonetheless increased compared with control patients. Future research is necessary to explore the mechanism by which psoriasis increases risk for certain infections, particularly soft-tissue and respiratory infections. As study limitations, investigators noted the risk for residual confounding and detection bias implicit in using hospital records. Increased psoriasis severity did not appear to influence risk for infection, suggesting that disease severity may have not been properly captured. Despite those findings, these results provide evidence for an increased risk for serious infection and hospitalization in patients with psoriasis.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry.

Please see the original reference for a full list of authors disclosures.

Follow @DermAdvisor

Reference

Yiu ZZN, Parisi R, Lunt M, et al . Risk of hospitalisation and death due to infection in people with psoriasis: a population-based cohort study using the Clinical Practice Research Datalink [published online March 28, 2020]. Br J Dermatol. doi: 10.1111/bjd.19052

Go here to see the original:

Are Patients With Psoriasis at Increased Risk for Serious Infection, Hospitalization? - Dermatology Advisor

Significant Improvements Observed With Apremilast in Mild to Moderate Plaque Psoriasis – Monthly Prescribing Reference

Amgen announced positive topline results from the phase 3 study of apremilast (Otezla), a phosphodiesterase 4 (PDE4) inhibitor, for the treatment of adults with mild to moderate plaque psoriasis.

The multicenter, placebo-controlled, double-blind ADVANCE study evaluated the efficacy and safety of apremilast in 595 adult patients with mild to moderate plaque psoriasis. Patients were randomized to receive either apremilast 30mg orally twice daily or placebo for the first 16 weeks followed by all patients receiving apremilast in an open-label extension phase through week 32. The primary end point was the proportion of patients with static Physicians Global Assessment (sPGA) response of clear (0) or almost clear (1) with at least a 2-point reduction from baseline at week 16.

Results showed that apremilast met the primary end point achieving a statistically significant improvement in sPGA response at week 16 compared with placebo. In addition, the study met key secondary end points including at least 75% improvement from baseline in the percent of affected body surface area (BSA); change in BSA total score from baseline; and change in Psoriasis Area and Severity Index (PASI) total score from baseline.

The safety profile of apremilast was consistent with that seen in previous trials. The most commonly reported adverse events (5%) in either treatment group were diarrhea, headache, nausea, nasopharyngitis and upper respiratory tract infection.

Detailed results will be submitted for presentation at an upcoming medical meeting.

Many patients with mild to moderate plaque psoriasis who use topical therapies still have challenges managing their psoriasis, said David M. Reese, MD, executive vice president of Research and Development at Amgen. We look forward to discussions with the FDA about the potential to bring Otezla, which has already been prescribed to hundreds of thousands of patients with moderate to severe psoriasis, to more patients who may need additional therapeutic options.

Otezla is currently approved for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, and for oral ulcers associated with Behets disease. It is available in 10mg, 20mg, and 30mg tablets.

For more information visit amgen.com.

View post:

Significant Improvements Observed With Apremilast in Mild to Moderate Plaque Psoriasis - Monthly Prescribing Reference

COVID-19 Outbreak Briefly Derails Phototherapy Treatment Market; Sales to Pick up Pace Once the Pandemic Begins to Recede – Cole of Duty

The global economic downtick has become worrisome for most companies in the Phototherapy Treatment market. Hence, companies are vying opportunities to gain competitive edge over other market players to capitalize on value-grab opportunities. Gain full access on our recently published report on the Phototherapy Treatment market that highlights how companies are adopting alternative business strategies to stay afloat during debilitating times.

Assessment of the Global Phototherapy Treatment Market

Market Research Reports Search Engine (MRRSE) recently published a report which provides a deep understanding of the various factors that are likely to influence the prospects of the Phototherapy Treatment market in the forecast period (20XX-20XX). The study takes into account the historical and current market trends to predict the course of the Phototherapy Treatment market in the upcoming years. Further, the growth opportunities, drivers, and major challenges faced by market players in the Phototherapy Treatment market are discussed in detail.

Request Sample Report @https://www.mrrse.com/sample/10643?source=atm

Regional Outlook

The team of analysts at MRRSE, track the major developments within the Phototherapy Treatment sphere in various geographies. The market share, size, and value of each region are discussed in the report along with explanatory graphs, tables, and figures.

Competitive Outlook

This chapter of the report discusses the ongoing developments of leading companies operating in the Phototherapy Treatment market. The product portfolio, pricing strategy, the regional and global presence of each company is thoroughly discussed in the report.

Product Adoption Analysis

The report offers valuable insights related to the adoption pattern, supply-demand ratio, and pricing structure of each product.

Family physicians are playing a crucial role in diagnosing psoriasis in Canada

In Canada, the majority of the psoriasis patients are mainly diagnosed by family physicians rather than by dermatologists. The reason behind this is the lack of dermatologists and related services in Canada. For instance, according to a report published by the Economist Intelligence Unit, Canada had less than 2 dermatologists per 100,000 individuals in 2015, which is very less when compared with European countries. It has also been observed that family physicians typically prefer topical therapies than biologics/phototherapy to treat psoriasis conditions, while dermatologists prefer phototherapy more than the other available therapies/medications. This recent trend is boosting the phototherapy segment. While in the U.S. the growing population of adult women suffering from acne and psoriasis is an important factor driving revenue growth of the phototherapy segment. The population of adult women is rising with higher rates in North America than in European countries such as Germany, Italy, France and Spain. The growth in women adult acne conditions in North America is mainly due to increase in male hormonal (androgens) levels in females.

Complementary therapies to treat psoriasis conditions and combination therapies are recent trends in Western Europe, which are creating a positive impact on the phototherapy segment in the regional market

Complementary therapies such as balneotherapy along with UV radiation is quite popular in Western European countries. Balneotherapy is the oldest treatment method available to treat the psoriasis condition. In this treatment, the patient undergoes a bath in high mineralized brine, which causes a mechanical removal of skin scales and increases the sensitivity of skin to UV radiation. Combination therapies are set to witness high potential in austerity driven markets in Europe as noted by many clinic managers. Faltering out-of-pocket expenses for a service that is considered as a desire or luxury coupled with a tricky pricing of combination treatments involving a device and a drug are factors successfully helping in generating revenue in the market. This trend is very prominent in countries such as the U.K. and Spain.

Approved by the FDA to treat acne and psoriasis, blue light therapy dominates the North America and Europe phototherapy treatment market

By phototherapy type, blue light therapy dominated the North America and Europe phototherapy treatment market for psoriasis and acne, and is expected to be the most lucrative segment over the forecast period, with a market attractiveness index of 3.3. By the end of 2027, the blue light phototherapy segment is projected to reach more than US$ 1,000 Mn, expanding at a CAGR of 6.7% over the forecast period. Revenue from the Narrowband UVB phototherapy segment in the North America and Europe phototherapy treatment market for psoriasis and acne is expected to grow 1.9x by 2027 end as compared to that in 2017. The Red Light Phototherapy and Intense Pulsed Light (IPL) Phototherapy segments represent the lowest market attractiveness index of 0.3 each.

Availability of various treatments for acne and psoriasis and declining reimbursement rates are expected to hamper the growth of the phototherapy segment

Various treatments are currently available in the market to treat acne and psoriasis conditions. For instance, to treat acne conditions various drugs are available in the market such as topical/oral antibiotics and retinoid and chemical peels, among others. Due to a lot of available treatment options, physicians prescribe different treatments according to the patients skin nature and availability of drugs. Owing to the many treatment options, very few physicians prescribe phototherapy to patients. Furthermore, availability of non-office based treatments to treat acne and psoriasis conditions has a negative impact on the growth of the phototherapy segment. Furthermore, the decline of reimbursement pay and lack of adequate phototherapy units in the market are projected to hamper revenue growth of the phototherapy segment over the forecast period.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/10643?source=atm

Critical Market Information Enclosed in the Report:

Doubts Related to the Phototherapy Treatment Market Catered to in the Report:

Buy This Report @ https://www.mrrse.com/checkout/10643?source=atm

Why Opt for Market Research Reports Search Engine (MRRSE)?

Read the original here:

COVID-19 Outbreak Briefly Derails Phototherapy Treatment Market; Sales to Pick up Pace Once the Pandemic Begins to Recede - Cole of Duty

Biologic, Immunosuppressive Therapies Not Tied to Severe Outcomes From COVID-19 Infection – Dermatology Advisor

There is no indication that certain patients with psoriasis or patients who have received a renal transplant are at increased risk for hospitalization or death from coronavirus disease 2019 (COVID-19), finds study data published in the Journal of the American Academy of Dermatology. This is despite a patient population who were immunocompromised as a result of medication and of older age and likely possessing metabolic and cardiovascular comorbidities.

From February 20 to April 10, 2020, researchers conducted a retrospective, observational study with the aim of determining if patients of Verona, Italy, with chronic plaque psoriasis receiving biologic or other immunosuppressive therapies as well as those who has received renal transplantation had a greater risk for hospitalization or death from COVID-19 than the general population of the city.

The investigators extracted data from hospital electronic medical records of patients with psoriasis receiving biologic or other immunosuppressive therapies and patients who had received renal transplantation. The data were then compared with the records from the general population of Verona (n=257,353) provided by the national public database.

At study conclusion, 1.2% (n=3199) of the population of Verona were COVID-19 positive; this percentage included patients who survived COVID-19 and those who did not require hospitalization. Results demonstrated that none of the 980 patients with chronic plaque psoriasis receiving biologic agents were hospitalized and none died. The researchers noted that of the 243 patients who had received renal transplantation, 1 patient was admitted to hospital for fever and pneumonia but fully recovered. Patients with psoriasis receiving biologic therapy and those who had received a renal transplant demonstrated a higher prevalence of obesity, hypertension, diabetes, and history of cardiovascular disease, the study data revealed. These patients also tended to be older and were predominantly men, compared with the general population.

The absence of molecular or serological testing for COVID-19 in the study population, the considerable difference in patient sample size and that of the general population cohort, and the small number of hospitalizations and deaths in the patient group were cited by the researchers as limitations of the study. However, because the authors had access to the complete medical record for all members of the patient group, a notable strength of the study was that if there had been a case of hospitalization or death from COVID-19, it would have been detected.

Follow @DermAdvisor

Reference

Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G . Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment [published online April 21, 2020]. J Am Acad Dermatol. doi:10.1016/j.jaad.2020.04.085

Go here to read the rest:

Biologic, Immunosuppressive Therapies Not Tied to Severe Outcomes From COVID-19 Infection - Dermatology Advisor

What Are The Different Types of Psoriasis? – HealthCentral.com

On this page:BasicsPlaque PsoriasisScalp PsoriasisNail PsoriasisGuttate PsoriasisInverse PsoriasisPustular PsoriasisErythrodermic PsoriasisPsoriatic Arthritis

With 125 million people in the world who have psoriasis, chances are you know someone who has the condition. But what you may not know is that there are several types of the chronic skin disease. They tend to get lumped in with the most common one: plaque psoriasis, which accounts for a whopping 80% of all cases. But there are six others that look, act, and may even be treated differently than the rest. Knowing which one you have can help you get better, faster.

Red, scaly, painful patches or bumps on your skin are the telltale signs of this inflammatory skin condition. It happens when your skin cells turn over at a way-too-fast rate (10 times faster than normal), causing a pile up of cells on the skins surface that form those angry, red patches, or plaques. Why this happens isnt so clear, but researchers believe psoriasis is caused by a mix of genetics, an overactive immune system, and triggers such as bacterial infection, skin trauma, smoking, medications, and obesity, just to name a few.

As we mentioned above, there are seven different types of psoriasis:

Theres also psoriatic arthritis, a combo of psoriasis and arthritis. Heres what you need to know about the causes and treatments for each one.

This is the type youre probably thinking of when someone mentions psoriasis. Its characterized by clearly demarcated, raised, red, scaly patches called plaques that appear most commonly on your elbows, knees, scalp, and back (but they can pop up anywhere on the body).

Because it accounts for 80% of all cases, plaque psoriasis tends to get the most press. Its the type addressed in most psoriasis drug commercials, and celebs including reality star Kim Kardashian and singer Cyndi Lauper have both been vocal about being plagued with plaques.

The cause for all cases of psoriasis stems from a combo of genetics, immune dysfunction, and triggers. People who have psoriasis are also more likely to have other inflammatory diseases such as Crohns disease, heart disease, or diabetes, suggesting some link between the underlying inflammation.

A study in Archives of Dermatology that looked at over 100,000 patients with psoriasis found those with severe psoriasis had a 46% greater chance of having diabetes than those without the skin disease.

There are several treatments that target plaques. Your physician will decide which one is right for you based on your general health, any underlying conditions, and the severity of your plaque psoriasis. Your options include:

Research suggests that biologics for psoriasis might help with those other inflammatory diseases linked to the skin condition, too. A study in Cardiovascular Research found that treating psoriasis with biologics helps reduce the plaque buildup in the arteries, which leads to heart attacks and strokes.

However, once your skin plaques disappear, youre not necessarily in the clear. Exposure to your triggers can bring on a new bout of plaque psoriasis. Only 10% of people are lucky enough to have whats called spontaneous remission, when your skin clears up forever and you never have a flare up again.

If youre scratching your head over an itchy scalp condition that wont clear up with a traditional dandruff shampoo, you may have scalp psoriasis. This type can go hand-in-hand with plaque psoriasis (see above), or even appear in those who dont have any history of the skin disorder at all.

Its often confused with dandruff, because, well, it itches and causes flakes, only these flakes are typically silvery-white and scaly. You might also have painful red scales or silver plaques on your head. In severe cases, scalp psoriasis appears as thickened, crusty patches of skin not only on the hairline, but also on the forehead, back of the neck and near the ears.

Unlike dandruff, scalp psoriasis doesnt come and go with the weather, hormonal fluctuations, or changes in hair products.The cause is the same as other types of psoriasis: an overactive immune system, genetics, and triggers such as stress and certain medications. But in this case, the plaques that show up may only show up on your scalp.

Mild cases can be nipped in the bud or improved with salicylic-, coal-tar-, or clobestasol propionate-containing (a topical steroid) shampoos. More severe cases may require systemic or biologic drugs, oral treatments, light therapy, or a combination of treatments. Unfortunately, you may lose some hair with some of these treatments, which is usually temporary.

If youve nailed it with psoriasis, then you know all too well that this type brings pitted, discolored, thickened, and even deformed fingernails and/or toenails. In severe cases, the nail plate can lift from the nail bed and you may see some gunk or even blood in between.

Of all the people who have some type of psoriasis, up to 50% will also have nail psoriasis. Like scalp psoriasis, it often comes along with plaque psoriasis, but it can also accompany other types or appear all on its own, too. Those with psoriatic arthritis will have an 80% chance of having nail psoriasis, too.

The same underlying causes as plaque psoriasis are at play here, too, revving up your skin cell production. Nails are considered part of the skin (theyre literally made up of skin cells), which is why they are also affected by the disease.

Typically, mild cases are treated with topical ointments rubbed into the nails such as:

More severe cases might require:

This type doesnt bring large plaques, but instead little red bumps smaller than a fingertip. You can wind up with hundreds of them scattered on your arms, legs, and torso.

About 10% of all psoriasis cases are the guttate type. You can have a mild case with just a few spots in one area, a moderate case that covers up to 10% of your body, or a severe breakout that leaves most, or even all, of your body covered in bumps.

This type often stems from a bacterial infection such as strep throat, an upper respiratory infection, or tonsillitis. There is also a genetic component. If a family member has had guttate psoriasis, youre more likely to get it, too.

Because guttate psoriasis is commonly triggered by infections, once you treat the infection, the psoriasis usually goes away, too. If the skin condition lingers, or you have a severe case, your physician may want to treat your symptoms with topical steroids and/or phototherapy, artificial UVB light that halts the inflammatory process.

This type affects fewer than 10% of people with psoriasis. Its called inverse psoriasis because it appears in unusual places such as the groin, armpits, bellybutton, genitals, under the breasts and behind the knees. Often, its accompanied by one of the other types of psoriasis listed here.

The same underlying culprits can lead to this type, only its brought on by sweat and friction. Thats why its commonly found in areas where there is skin-to-skin rubbing and moisture. Weight seems to be a factor, too. If youre overweight, youre more likely to have skin folds, prime spots for inverse psoriasis.

The gold standard is typically topical steroids and ointments in those vulnerable spots where moisture and friction are likely. If those dont work, phototherapy, and systemic treatments are an option.

As the name implies, this type causes pus-filled bumps. These white spots can appear anywhere on your body, but most commonly the hands and feet. The bumps come on suddenly and look infected, but theyre not.

The real danger here is damage to the skins barrier, the outermost protective layer of your skin. That means your skin cant retain water or nutrients, while also allowing bacteria and other irritants to get a fast pass into your body. As a result, in some cases, pustular psoriasis can be deadly, so make an appointment with your doctor asap, if you develop it.

There are a few sub-types of pustular psoriasis:

At the risk of sounding like a broken record, genes are to blame. But researchers have dug deeper and discovered a specific gene mutation that may be responsible for pustular psoriasis.

A study in the American Journal of Human Genetics IDd the gene AP1S3. If you have this particular genetic predisposition, the triggers for pustular psoriasis are often infection, stress, hormonal changes such as pregnancy, and exposure to chemicals. Also, certain drugs such as OTC pain relievers and anti-inflammatory drugs, penicillin, and some antidepressants such as lithium can trigger a flare. Stopping a course of steroids too fast can bring on a flare of pustular psoriasis, too.

Your doctor may prescribe a topical retinol or an immune-suppressing biologic such as Remicade (infliximab) to calm inflammation and stop the bumps. In severe cases, you may get a combo of a biologic and an oral immune-calming med such as Trexall (methotrexate) to get it under control.

The rarest of all psoriasis types, erythrodermic psoriasis affects only 2% of those with psoriasis. This type causes redness from head to toe, as if your skin has been burned. Even worse, its possible that your skin could peel off in sheets.

As with the pustular type, erythrodermic psoriasis severely compromises the skins protective barrier, so swift medical attention is a must. You can also develop fever, chills, swollen, painful joints, and rapid heart rate.

This type can be triggered by a bad sunburn, an infection, drug reaction, stopping a medication too abruptly, steroid use, stress, and alcoholism.

Your doctor will likely start with an immune suppressant. To soothe your sore skin, you may be prescribed topical steroids, itch-suppressing medications, or prescription pain treatments.

An estimated 30% of people with psoriasis also have or will develop psoriatic arthritis, or PsA, a chronic autoimmune condition that affects 2-3% of the population. While psoriasis affects the skin, psoriatic arthritis affects the joints and some parts of the body where ligaments and tendons are attached to the bone, particularly in the fingers, toes, wrists, knees and spine. The result is stiffness, swelling, pain and, if not caught early, irreversible damage, which is why early diagnosis and treatment are important.

PsA is an autoimmune disease. That means your immune system gets its messages mixed up and attacks healthy tissue, in this case, of your skin and joints. Youre also more likely to develop PsA if you have a family history of it (40% of people who have it also have a family member who has it, too), you already have psoriasis, and youre between the ages of 30 and 50.

If you have this condition, youll want to see a rheumatologist, a doctor who specializes in arthritis. Treatments can range OTC non-steroidal anti-inflammatory drugs (NSAIDs) such as Advil (ibuprofen) to disease-modifying antirheumatic drugs (DMARDs), including methotrexate, that work by slowing your immune system and your bodys inflammatory response. If those dont work, biologics may be considered.

Both can be itchy and cause shedding onto your hair, clothes and furniture. But the similarities stop there. Scalp psoriasis, like plaque psoriasis, is an autoimmune disease that is usually chronic and incurable. On the other hand, dandruff can go away on its own or be treated with a mild dandruff shampoo (if its caused by dry weather, for instance) and doesnt require medical attention.

Yes. In fact, keeping nails clean and trimmed and not biting them can help, and the cosmetic benefit can make you feel better about your nails. Be sure to tell your manicurist you have psoriasis because its easily mistaken with a fungal infection, which is contagious. One tip: Avoid long soaks. It robs your nails of moisture and that can make your nail psoriasis worse.

Around 85% of people develop skin psoriasis first or at the same time as psoriatic arthritis. Only about 15% get arthritis symptoms before the skin disease. Psoriasis is most likely to develop between 15 and 35 years old, while psoriatic arthritis shows up between ages 30 and 50.

For some people, guttate psoriasis, characterized by spotty, scaly lesions on arms, legs and torso, may come once and never return. It is commonly triggered by infections, like a common cold or strep throat. Once you treat it, it may be gone for good.

Go here to read the rest:

What Are The Different Types of Psoriasis? - HealthCentral.com

Visual Functions in Psoriatic Arthritis Sine-Psoriasis May Be Linked to Systemic Inflammation – Dermatology Advisor

Dry eye and subclinical abnormalities in visual functions in patients with psoriatic arthritis (PsA) sine-psoriasis may be related to systemic inflammation, according to study results published in the Journal of Clinical Medicine.

In this noninterventional, cross-sectional study, the disease activity of patients aged 18 to 65 years with diagnosed PsA and no evidence of skin psoriasis (n=40) was assessed by an experienced rheumatologist; a healthy control group (n=35) was also included in the study. All patients received a standard ophthalmology exam, which included best-corrected visual acuity, ocular surface disease index questionnaire, Schirmer test, and tear film breakup time (BUT). Standard automated perimetry, spectral-domain optical coherence tomography, and fundus perimetry scans were performed in all patients.

Researchers evaluated 80 and 70 eyes from patients in the PsA group (72.5% women; mean age, 5214 years) and the healthy control group (60% women; 48.713.8 years) , respectively. The best-corrected visual acuity of patients in the PsA group and the healthy control group were similar, and an abnormal ocular surface disease index (OSDI) was observed in 60% of patients with PsA. Prevalence of dry eye was significantly greater in the PsA group compared with the healthy control group (P <.0001). Approximately 75% of patients in the PsA group (n=30) were definitively diagnosed with dry eye (39.9% with BUT <10 sec; 23.4% with Schirmer 5 mm; 36.7% with both BUT <10 sec and Schirmer 5 mm).

Researchers indicated a positive correlation between OSDI and erythrocyte sedimentation rate (ESR; r=0.6; P <.001), In terms of the Schirmer test values, a negative correlation was observed between the scale of wetness and ESR (r=-0.43; P =.007). Results from standard automated perimetry indicated a higher mean deviation and pattern standard deviation in the PsA group compared with the healthy control group (P <.0001 and P =.005, respectively). In addition, ESR and C-reactive protein (CRP) showed a positive association with pattern standard deviation (r=0.3 and r=0.4; P =.04 and P =.01, respectively), while CRP was also correlated with mean deviation (r=-0.4; P =.01). Patients with PsA and the control participants demonstrated a similar visual field index (range, 98%-100%).

Assuming that relevant signs of systemic disease may be revealed as abnormalities occurring in the eye, a clinical evaluation of retinal morphology and function should be performed in order to detect subclinical damage of the visual system early, the researchers advised. In addition, careful ophthalmologic examination of patients with PsA sine-[psoriasis] may produce valuable clinical information on disease activity status. Using either [standard automated perimetry] or [fundus perimetry] and [optical coherence tomography] assessment could allow the detection of early changes in visual function even before clinically detectable retinopathy. These ancillary tests may serve as a useful monitoring tool over the entire course of the disease.

Reference

Chimenti MS, Triggianese P, Salandri G, et al. A multimodal eye assessment in psoriatic arthritis patients sine-psoriasis: evidence for a potential association with systemic inflammation. J Clin Med. 2020;9(3):E719.

This article originally appeared on Rheumatology Advisor

Read the original:

Visual Functions in Psoriatic Arthritis Sine-Psoriasis May Be Linked to Systemic Inflammation - Dermatology Advisor

Meet the Scientists on the Frontlines of Psoriasis Research – HealthCentral.com

Editor's Note: This story is part of a new series on HealthCentral called "Get Your Ph.D.!", which is geared toward people who've got the basics of their condition down and want to up their expertise. Who's ready to go pro?!

If psoriasis had a street name, it would be known as Slim Shady. Not only does the exact cause of this condition baffle even the best of scientific minds (genetics and an overactive immune system are possible culprits, as are triggers like stress, skin trauma, and weight gain), but its characteristic itchy and painful lesions can crop up anywhere from head to toe. In the world of skin conditions, psoriasis is all kinds of sly.

While there are effective treatments available to manage symptoms and stop them from getting worseincluding topicals, ultraviolet light therapy, oral meds, and biologics, which target the immune systemthere is yet to be a foolproof, one-size-fits-all cure. Whats more, larger implications about the relationship between psoriasis and other diseases are still a question mark. Now, thanks to groundbreaking studies from some seriously smart researchers, there is new hope for a better understanding and treatment of the condition. We talked with three of these doctors to find out what theyre working on. Caution: Majorly impressive science ahead.

MEET THE EXPERT:

Title: Head of the Lab of Inflammation and Cardiometabolic Diseases at the National Heart, Lung, and Blood Institute (NHLBI)

Research: Exploring the link between psoriasis inflammation and heart disease

Skin health isnt usually among the conditions a cardiologist studies, let alone treats, but for Nehal N. Mehta, M.D., psoriasis plays a starring role in his research.

It started with a single patient. I met a 45-year-old physician who had been having recurrent heart attacks with no real risk factors, and when I examined him, I saw a patch of psoriasis on his right inner thigh that hed had since med school, Dr. Mehta says.

It could have been nothing, but then again, there were no other clues to go on. Dr. Mehta started wondering. On a hunch, he and his team began examining scans of people with psoriasis, and what they found was startling: The condition was not just skin deep. When you look at these images, theres inflammation everywherein the joints, in the skin, in the liver, in the spleenthis is a whole-body disease, Dr. Mehta says.

Then they applied those findings to people who also had a heart attack. It was a eureka moment. Even if you accounted for all the other risk factors people had for cardiovascular disease, if they had psoriasis, it increased their risk for a heart attack by 53 percent, Dr. Mehta says.

As it turns out, the same overactive immune cells in the skin that lead to psoriasis can also be found in the heart arteries. In the arteries, however, the immune system is associated with plaque buildupa major risk for heart attack. So if you treat the psoriasis thats causing the immune system to be overactive, says Dr. Mehta, you can also reduce the risk of heart artery disease. Treating remote inflammation in the body can reduce the plaque that leads heart disease and heart attack, he says.

The treatment he uses is a biologic medicationa protein-based injectible drug created from living cells that targets the areas of the immune system associated with psoriasis. Using a biologic treatment redistributes fat in your body in a beneficial way, so youre not only improving the skin but also HDL, the bodys good cholesterol, as well as glucose levels which reduces the risk for diabetes.

Why are these findings so crucial? In addition to showing that patients with psoriasis may warrant early heart disease intervention, says Dr. Mehta, it also reveals a new risk factor (and treatment) for people with heart conditions. Along with diabetes, hypertension, high cholesterol, family history, and smoking, inflammation from psoriasis is an important variable in cardiac events. You have patients who are now learning about a sixth risk factor for heart attacksits pretty wild, he says.

MEET THE EXPERT:

Title: Director of the Psoriasis and Phototherapy Treatment Center and Professor of Dermatology at University of Pennsylvania Perelman School of Medicine

Research: Studying the benefits of at-home phototherapy treatment

Long used to help treat psoriasis, Ultraviolet B phototherapy improves symptoms by penetrating the top layer of the skin with narrowband UVB light, preventing skin cells from growing too quickly. Patients prefer it to systemic medications because its virtually free of side effects. But phototherapy is expensive, time consuming (it requires 12 weeks of in-office treatments), and not always covered by insurance.

Enter: Joel Gelfand, M.D., the director of the Psoriasis and Phototherapy Treatment Center and a professor of dermatology at University of Pennsylvania Perelman School of Medicine. Dr. Gelfand is studying the effects of at-home phototherapy as a lower cost, more accessible alternative to in-office treatments, so that more people can benefit from it.

Helming whats known as the LITE Study, Gelfand and his team are conducting an ongoing randomized, controlled study of 1,050 patients to compare the effectiveness of home-based phototherapy devices to office-based treatments. The study charts the success rate and safety of 12 weeks of therapy in both environments. It also documents the outcomes for three different skin toneslight skin, olive to light brown skin, and dark brown to black skinto measure tolerance and effectiveness.

Up until now, there hasnt been enough data on at-home therapies, and this has led to decisional uncertainty from patients, dermatologists, and insurers, Dr. Gelfand says. What were doing is an example of real-world pragmatic research designed to shift the practice of medicine in a way thats more patient-centered.

Not only does the study aim to provide important data on treatment response in patients of different skin colors, but it will ultimately help broaden the options for anyone struggling with this disease. Says Dr. Gelfand, Were trying to make phototherapy accessible and affordable to anyone who needs it.

MEET THE EXPERT:

Title: Assistant Professor at the University of Texas Southwestern

Research: Slowing cell metabolism to prevent hyper-skin growth linked to psoriasis

Heres the thing about psoriasis treatment: Because most medications broadly target the immune cells responsible for the disease in a system-wide way, they come with some serious side effects that are, in a word, uncomfortable. But, what if by simply targeting certain cell pathways the disease could be treated without side effects?

This is the question that lead Richard Wang, M.D., an assistant professor of dermatology at the University of Texas Southwestern, to start looking at glucose transport and metabolism to understand their roles in cell growth and division in conditions like psoriasis, which is characterized by skin overgrowth.

In a lab experiment, Dr. Wang and his team blocked glucose transport in the skin cells of mice using genetic and chemical inhibitors. Glucose is critical for cell survival and cell growth, Dr. Wang says. To maintain normal functioning throughout the body, glucose moves through transporters in very specific pathways so that growth and division of cells is controlled.

In people with psoriasis though, inflammation sends cells false signals that an infection is happening and those glucose transporters, which regulate the amount of glucose in cells, respond by letting more glucose in. All this extra glucose causes cells to divide, grow, and thickenresulting in the visible scales and inflamed skin characteristic of psoriasis. By blocking those glucose transporters in the mice, we were able to shut this process down, inhibiting the growth of skin cells and controlling inflammation without disrupting the skins normal functioning, Dr. Wang says.

While Dr. Wangs research is ongoing, the promise is clear: There is potential for a new, more targeted chemical inhibitor topical agent to treat humans with mild-to-moderate psoriasis without the side effects of traditional treatments, he says.

Read more from the original source:

Meet the Scientists on the Frontlines of Psoriasis Research - HealthCentral.com

Psoriasis and Diet: What’s the Link? – HealthCentral.com

Editor's Note: This story is part of a new series on HealthCentral called "Get Your Ph.D.!", which is geared toward people who've got the basics of their condition down and want to up their expertise. Who's ready to go pro?!

Scientists have long known that obesity and psoriasis go hand-in-hand. Like chips and salsa or gin and tonic, if you have one disease, youre likely to have the other. The reason is that a high BMI can lead to inflammation in the body, which increases the risk for developing the challenging skin condition known as psoriasisor worsening existing symptoms if you already have it. Now, a new study published in the Journal of Investigative Dermatology suggests there may be another mechanism at work: Fat cells themselves may not be the culprits, say researchers, but rather specific types of foods are to blame.

In the study, conducted at the University of California, two groups of mice were fed different diets. Once group got a typical mouse meal; the other one was given a characteristic Western diet (basically, the mouse equivalent of a moderate-to-high fat, processed-sugar diet that mimicked what humans would eat on the same meal plan). The mice kept it up for four weeks, after which scientists took stock of their skin, and found that the creatures whod been chowing on the rodent version of burgers, fries, and shakes showed visible inflammatory changes including redness, scales, and thickened skinthe same hallmark symptoms consistent with human psoriasiseven if the mice hadnt appreciably gained weight.

This is important because many people think that its obesity alone that leads to the increased risk for psoriasis, says senior study author Sam T. Hwang, M.D., Ph.D., department chair and professor of dermatology at the University of California Davis School of Medicine. What this shows is that dietary changes can have a radical impact on the skinso its not just weight that makes a difference for developing psoriasis, but the types of foods you eat.

These so-called Western foods are typically high in saturated fat (butter, red meat, cheese and other dairy products made from whole milk, for example), plant-based oils (such as palm oil, coconut oil, and canola oil) and processed ingredients, like those in many baked goods. The foods also contain high levels of simple sugars, found in fruit juices, soda, candy, and even some whole fruits like apples, bananas, and watermelon.

So, what is it about these foods, common in American diets, that causes inflammation in the first place? Researchers believe they alter the composition of the microbiome, those billions of bacteria living in your gut that help maintain general health and the health of your immune system. Changing the balance of these bacteria through diet may ultimately lead to an inflammatory response related to psoriasis.

To break it down even further (we know, its complicated), high-fat foods cause bile acids from your gall bladder and liver to go into the gut to help with digestion, says Ronald Prussick, M.D., an assistant clinical professor of dermatology at George Washington University and medical director of the Washington Dermatology Center. These acids then cause bad bacteria to form, leading to inflammation inside the body.

What this all means: The study proposes that what you eat can alter the gut microbiome, causing changes in bile acid levels, which can affect inflammation.

This theory was tested in the study when the researchers administered cholestyramine, a drug used to lower cholesterol (high levels of which are found in fast foods and other western fare), to the mice and found that it helped reduce the risk of skin inflammation. Cholestyramine was shown to bind to bile acids in the intestine and release through the stool, allowing for inflammation to be lowered in the mice, Dr. Hwang says.

Doctors have long maintained that there is no single food that can treat or cure psoriasis, and thats still true. But if you have the skin condition or are at risk for the disease (which is frequently genetically determined), limiting or eliminating foods high in saturated fats and simple sugars can lessen the chances for inflammationand therefore possibly psoriasis, Dr. Hwang says.

What to eat instead? A Mediterranean-type diet, characteristically rich in healthy fats and omega-3 fatty acids, is known to help fight inflammation. It includes foods such as olive oil, avocados, nuts, seeds, fish like salmon and lake trout, and some meat or dairy from grass-fed animals, as well as fresh vegetables and fruits low on the glycemic index, like berries. Switching to a healthier diet can increase the chances of treating psoriasis more effectively, says Dr. Prussick.

Additionally, Dr. Prussick suggests cooking on lower heat by stewing, poaching, boiling, and steaming foods rather than grilling, frying, or toasting them. Heat causes sugars in foods to bind to proteins, known as advanced glycation end products (AGEs), which causes more inflammation, he says. He also recommends cooking with acids such as vinegar or lemon juice, which can reduce AGEs by 50%.

Visit link:

Psoriasis and Diet: What's the Link? - HealthCentral.com

Psoriasis guidelines reflect rise of NB-UVB, targeted and home therapies – Dermatology Times

The latest American Academy of Dermatology-National Psoriasis Foundation phototherapy guidelines incorporate several advances in efficacy, safety and patient convenience that were unavailable a decade ago.

RELATED:Biologic guidelines for psoriasis let providers choose

Weve come a long way in the field of phototherapy over the last 10 years, says M. Alan Menter, M.D. He is chairman of dermatology at Baylor University Medical Center, co-chair of the AAD Psoriasis Guideline Workgroup and founder of the International Psoriasis Council.

To produce the phototherapy guidelines, Dr. Menter and co-authors reviewed available data regarding previous phototherapy modalities, along with newer technologies including narrowband UVB (NB-UVB). With a wavelength of 290 to 320 nm, NB-UVB offers greater specificity and targeting for psoriasis and eczema than does broadband UVB (BB-UVB, 290 to 400 nm).

Formerly the mainstay of phototherapy, BB-UVB has been replaced by newer modalities. As monotherapy for adults with generalized plaque psoriasis, guidelines state, BB-UVB provides less efficacy than does NB-UVB, oral psoralen plus UVA (PUVA) or topical PUVA. Very few dermatologists still use oral PUVA, says Dr. Menter, although it works well for resistant psoriasis.

Now we also have intense electrodes and dye lasers, which are smaller lamps that penetrate much better for focal areas such as thick psoriasis patches on the elbows or knees, he says. Such technologies include excimer lasers (308 nm), targeted NB-UVB (311 to 313 nm) and pulsed-dye lasers (PDLs).

Whichever technology one chooses, guidelines emphasize the need to tailor dosing to the patients skin type. For example, minimal erythema dose (MED) testing with NB-UVB should begin at 250 mJ/cm2 for patients with skin types I and II, versus 350 mJ/cm2 for types III and IV.

Whereas Goeckerman therapy was a difficult, messy and time-consuming combination of light therapy and tar treatment, Dr. Menter says, physicians can supplement NB-UVB with concomitant topical therapies such as vitamin D analogs, retinoids and corticosteroids to potentially boost efficacy.

Disclosures:

Dr. Menter reports no relevant financial interests.

References:

Elmets CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019;81:775-804.

Visit link:

Psoriasis guidelines reflect rise of NB-UVB, targeted and home therapies - Dermatology Times

The Dermatologist Whos Obsessed With Sun Damage – The Cut

Photo: Courtesy of the Laser & Skin Surgery Center of New York

Dermatologist Robert Anolik treats some of New Yorks most discerning faces his clients include Stephanie Seymour and Kelly Ripa but that doesnt stop him from worrying about fictional characters, too. Over the past few weeks, he, his wife, and their 7- and 5-year-old kids have been watching The Singing Detective, an 80s-era BBC show about a hospitalized mystery writer.

It has great music in it, but my kids keep asking me all these questions about the main character, whos covered in psoriasis and has psoriatic arthritis, says Anolik, a dermatologist at the Laser & Skin Surgery Center of New York. All I can think about is how that patient could be helped dramatically today with the approach of medical dermatology.

Anolik was a protege of the late Dr. Fredric Brandt, who was well-known in the beauty world for popularizing Botox. But what initially drew him to cosmetic dermatology wasnt injections or chemical peels, but DNA, RNA, and proteins. As a molecular biology major at Princeton, he spent one summer at the Institute for Genomic Research, studying the science of sequencing the human genome. In medical school, I saw how protein sequence analysis touched every field in medicine, but particularly skin and aging, he says. I approach skin with that kind of molecular framework to make it healthy and beautiful.

During his dermatological training at NYU, Anolik landed a fellowship with famed dermatologist Roy Geronemus, director of the Laser & Skin Surgery Center. Brandt was also part of the practice, and when he wanted to divide his time more evenly between his Miami and New York practices, Anolik became his official associate.

He wanted someone who also had laser expertise, which he knew I had, says Anolik. Even though we looked like total opposites, our personalities clicked.

Five years later, tragedy struck and Brandt took his own life. Anolik seamlessly took over, with high-profile clients now trusting their complexions to him.

These days, until he can see those patients again, hes been volunteering at Bellevue Medical Center, tending to patients with post-op wounds and other surgery-related issues. Stuff that needs attention by a physician, he says. Theyre all so overwhelmed, so hopefully I can help decrease the burden.

Anolik spoke with the Cut about the calming presence of Angela Lansbury, his complicated relationship with fruit, and why now is the perfect time to exfoliate.

Whats your definition of beauty? The Keats line beauty is truth; truth beauty is a chestnut for a reason. When I look at a face, my goal is to reveal its truth, that is to let its beauty become manifest, which is why I work very hard to eliminate distortions, both external (e.g., sun damage) and internal (e.g., psychological negativity).

What do you think of when you hear the term clean beauty? I get wary when I hear it. I believe in the sentiment that drives the clean beauty concept. As a scientist, however, I also believe in rigorous study over intuition and guesswork. Just because something grows on a tree doesnt mean its safe and/or effective. And even the cleanest ingredients in too high a quantity can be dangerous. For example, drinking too much water will kill us. And, conversely, an ingredient that sounds strange or worrisomely artificial can, in fact, be beneficial. A word of caution for those experimenting with only clean or alternative therapies: If you believe something is strong enough to help you, its likely strong enough to hurt you as well. So dont overdo it! And be sure to consult with a board-certified dermatologist about safe strategies.

Where, if anywhere, in your beauty (or life) routine are you not quitethat clean, green, or sustainable? I drink diet soda. Its dumb and I know better, but I do it anyway.

Please fill in the blank as it pertains to beauty or wellness: I think about ______a lot. SUN DAMAGE.

What is the opposite of beautiful? An artificial appearance. Lips that are too big or faces that are frozen are not beautiful. And believe me, I cringe more than you do when its obvious someone has had work done. Just because we can do something in cosmetic dermatology, doesnt mean we should.

What is your morning skin-care routine? Alastin Gentle Cleanser or Neutrogena Ultra Gentle Cleanser, shave, sulfacetamide wash to reduce shave irritation, LaRoche-Posay Anthelios Melt-In Sunscreen Milk SPF 60, SkinMedica HA5 Rejuvenating Hydrator.

Whats the last product you use every night? A prescription retinoid, then moisturizer. Usually Alastin Ultra-Nourishing Moisturizer or Cerave Cream.

Who cuts your hair? Garren. Asking Garren to cut my hair is like asking van Gogh to paint on a milk carton. But hes my friend; he pretends not to mind.

Toothbrush of choice: My wife bought me a Sonicare but I still use the freebie from the dentist.

Razor of choice: Gilette Fusion 5.

Shaving cream of choice: Gillette Fusion Hydra Shave Gel Ultra-Sensitive.

Hand wash of choice: Dove Foaming Hand Wash.

Hand sanitizer of choice: Purell.

Fragrance of choice: Hermes Eau dorange verte Eau de cologne.

Bath or shower: Shower, with Olay Ultra Moisture Body Wash with Shea Butter, R&Co. Television Shampoo, Television Conditioner, and Acid Wash.

What was your first grooming product obsession? In third grade, I discovered mousse. Id blow-dry my hair with it. Maybe I watched St. Elmos Fire a few too many times.

Daily carry-all of choice: Prada nylon shoulder bag. A gift from Dr. Brandt. Prada was a favorite brand of his.

What do you splurge on? My wifes very particular about our sons footwear. Lots of tiny pairs of Air Jordans, Converse, Vans, and Adidas Gazelles by our front door.

What is your classic uniform (under your lab coat)? Black or navy Brooks Brothers pants and black or navy Ralph Lauren crew neck sweater.

Whose shoes are you usually wearing? Greats Royale sneakers.

What do you own too many of? Medical journals. I know at this point that the past issues are all online where I read the new ones, but theres something enjoyable about referencing them with your handwritten notes. At some point, theyll find their way to the recycling bin.

Any secret talent or skill you possess? I can juggle.

What is your own personal definition of misery? Fruit of any kind in my desserts. I love cake but Im crushed when it turns out to be carrot, and I cannot get enough ice cream but I pout when the flavor turns out to be strawberry.

What is your own personal definition of glee? Getting my cholesterol tested. I dont eat all that well, and Im not great about exercising, but my cholesterol is always low. I find that so gratifying.

Favorite way or place to spend a weekend? Nantucket. My wifes family has a house there, and they make fun of me when I wear my aqua socks to the beach.

What do you most often disagree with others about? People who insist they need to get a base tan before a tropical vacation. This is nuts. You should avoid getting a tan before your tropical vacation and during your tropical vacation and after your tropical vacation. Heres what you should get instead: sunscreen and sun-protective clothing.

What must you adjust or fix when you see it done incorrectly? Bad Botox on someone who comes in for a first-time consultation.

Favorite CBD product: Ridgway Hemp Love Balms.

What calms you down? Seinfeld reruns on Netflix. And when Im really feeling stressed: Murder, She Wrote reruns on Amazon Prime (dont judge).

Comfort food: Oreos and milk.

Vice snack: Chili-roasted pistachios and Empire Bakery house-made Twinkies.

What do you foresee as the top beauty and wellness trends for 2020? Combination therapy, specifically more one-day treatments that combine multiple lasers and injections. We have been developing this for years and are now presenting safety data on the subject.Also, laser-assisted drug therapy, such as resurfacing lasers followed by topical applications of skin-brightener serums and platelet-rich plasma. Heres what I hope is the top beauty/wellness trend in 2020: a public repudiation of non-board-certified dermatologists performing cosmetic dermatology procedures on people.

What treatment at your practice is misunderstood and should be morepopular? Laser resurfacing. Granted, this is already a very popular treatment in our office, but I believe it should be even more popular. Somepatients come in with misinformation that laser resurfacing thins theskin. Nothing could be further from the truth. In fact, it does theopposite. It targets collagen-producing cells in the dermis andgenerates a stronger, more resilient skin.

What treatment is currently your favorite (understanding that thiscould change all the time)? Botox. And it has been for years. Precise treatment avoids artificial outcomes and allows for a refined, rejuvenated, lifted, rested appearance.

What activity do you do when the stress becomes too much these days?Cook. Ive been spending a lot of time with my cast-iron skillet. My cast-iron pizza is a favorite.

What have you been binge-watching? Ozark season three for suspense how good is Tom Pelphrey as Laura Linneys brother? And Cheers for laughs.

What has been an upside to this crazy time for you? My time with my wife and young sons, except during the screaming. And the homeschooling. And the cleaning.

Whats a good beauty treatment for someone whos stuck at home? Exfoliation. A downside of exfoliation is it can sometimes leave the skin dry and flaky, but if youre staying home, thats okay!

Conversely, what in your own grooming routine are you less on top of these days?Shaving, although my wife prefers a cleaner look, so early signs of a beard appear only now and then.

When this is all over, what are the first three to five things youll do or places youll go? The office will be my first stop! I miss my amazing patients! I expect Ill be there in overtime mode for a while getting everyone in. Id love a flat white at Laughing Man in Tribeca, maybe a burger at Odeon. Also we watched King Kong with the kids during quarantine, so my oldest wants me to take him to the top of the Empire State Building. He thinks King Kongs going to be there. I havent had the heart to set him straight.

Get the Cut newsletter delivered daily

Read the original post:

The Dermatologist Whos Obsessed With Sun Damage - The Cut

COVID-19 and psoriasis: Risks and precautions – Medical News Today

People with psoriasis may be wondering how COVID-19 might affect them. COVID-19 is a new illness resulting from infection with the novel coronavirus, or SARS-CoV-2.

At present, it is unclear how COVID-19 may affect those with psoriasis, which is an immune-mediated condition. This mean the condition occurs as a result of abnormal immune system activity. Scientists are also unsure about how it may impact the treatment of these individuals.

Some treatments for psoriasis, which are immunosuppressive medications, may increase the risk of a COVID-19, or of severe illness due to the virus. However, the effects are still unknown.

Stay informed with live updates on the current COVID-19 outbreak and visit our coronavirus hub for more advice on prevention and treatment.

Keep reading to learn more about the potential risks of COVID-19 for those with psoriasis, including the precautions that people can take to reduce their risk of developing COVID-19 and its complications.

The details of how COVID-19 affects those with psoriasis remain unknown, but there is not yet evidence to suggest that it affects them differently than people without the condition.

According to the National Psoriasis Foundation (NPF), if a person is not taking an immunosuppressive medication and is free from other underlying diseases, there may be minimal additional risk of them contracting SARS-CoV-2 relative to the rest of the population.

However, as the virus is highly transmissible, spreads rapidly, and replicates rapidly, everyone is at risk. Even asymptomatic people can transmit the virus to others.

The NPF note that people with severe psoriasis, such as those who are on immunosuppressive therapies or have other medical conditions, probably are at higher risk of infection.

As psoriasis is a chronic immune-mediated condition, some people may take immunosuppressant drugs to keep their symptoms under control.

These medications can reduce immune function, which may increase the risk of infection with SARS-CoV-2 or other infectious agents. Immunosuppressive drugs could also increase the risk of severe symptoms.

According to the Centers for Disease Control and Prevention (CDC), conditions or medications that weaken the immune system and cause people to become immunocompromised increase the risk of severe COVID-19.

The International Psoriasis Council (IPC) recommend that people with psoriasis who receive a COVID-19 diagnosis discuss discontinuing or postponing their use of immunosuppressant medications with their doctor.

However, the IPC caution that doctors should carefully weigh the benefit-to-risk ratio of immunosuppressive treatments on an individual basis.

The medical board of the NPF do not recommend that people with psoriasis stop their treatment unless they have an active infection. They suggest that those in high risk groups discuss their options with their doctor.

The CDC list the following as high risk:

The World Health Organization (WHO) and other expert bodies are still learning about the effects of COVID-19 on those with co-occurring conditions.

The WHO list the most common COVID-19 symptoms as:

They state that other possible symptoms include:

Some people with COVID-19 also report a loss of taste or smell.

Symptoms typically develop within 214 days of exposure to the virus. They range from mild to severe, although the majority of people experience a relatively mild form of the disease, which will not require specialist treatment in a hospital.

Some people may be asymptomatic, meaning that they have no symptoms, despite testing positive for the virus that causes COVID-19. Asymptomatic individuals can still transmit the virus to others, though.

People can reduce the risk of exposure to the novel coronavirus by:

Anyone who thinks that they may have become exposed to the virus should:

It is advisable to call ahead before presenting at an emergency facility in case they need to put safety measures in place.

The NPF recommend that people with psoriasis discuss their treatment with their doctor. A doctor may recommend continuing medications or taking a break from them.

It is important that people only adjust or stop their treatment after consulting with their doctor.

So far, there is no specific treatment or vaccine for COVID-19. In those who contract the virus and develop symptoms, treatment aims to alleviate these symptoms. Treatments include:

People who develop severe illness will require hospitalization. In the hospital, doctors may put them on oxygen or a ventilator, or provide other specialist care.

In some cases, doctors may speak to a person about participating in a clinical trial, which is very important in helping experts learn about the disease and find effective treatments.

People with psoriasis who develop COVID-19 should speak to their doctor about their psoriasis treatment while ill.

Those taking immunosuppressive medications will often need to stop treatment temporarily until their doctor says that it is safe to resume. The doctor will advise on other types of psoriasis treatment on a case-by-case basis.

When someone tests positive for the novel coronavirus, their doctor will provide them with instructions for recovery. They will also explain to the individual how to self-isolate to reduce the spread of the virus to others.

People with mild symptoms can typically recover at home, while those with severe illness often require a hospital stay.

It is difficult to determine the outlook for people with COVID-19 and psoriasis, but this generally depends on:

Data from China showed that 80% of people who develop COVID-19 have mild-to-moderate symptoms and recover well. Of the remainder, 13.8% develop severe disease, and 6.1% become critical and require intensive care.

Prompt medical treatment may improve the outlook of people with severe disease and reduce the risk of complications, which include pneumonia and organ failure. In some cases, COVID-19 can also lead to death.

At present, experts know little about the effects of COVID-19 on people with psoriasis.

However, it seems that those who are not taking an immunosuppressive medication and do not have another co-occurring disorder have a similar risk to the rest of the population.

People taking immunosuppressive therapies who receive a COVID-19 diagnosis should consult their doctor immediately. It is likely that the doctor will advise them to stop taking these medications until they recover.

There is no specific treatment for the novel coronavirus, but individuals can reduce their risk of contracting it by maintaining physical distance from others, avoiding unnecessary public outings, and practicing good hygiene.

Individuals with psoriasis should speak to their doctor about their specific case. A doctor will address any concerns that a person has, and they may adjust their treatment plan accordingly.

For live updates on the latest developments regarding the novel coronavirus and COVID-19, click here.

View original post here:

COVID-19 and psoriasis: Risks and precautions - Medical News Today

Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema – Yahoo Finance

WESTLAKE VILLAGE, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that it has enrolled the first patient in Phase 1/2b study of ARQ-252, a potent and highly selective topical small molecule inhibitor of janus kinase type 1 (JAK1), in adult patients with chronic hand eczema.

Hand eczema is one of the most common skin diseases, affecting approximately 8 million Americans, and currently there are no FDA-approved therapies for this affliction, said Howard Welgus, M.D., Arcutis Chief Medical Officer. We are delighted to begin enrollment in this Phase 1/2b study of ARQ-252, our topical JAK1 inhibitor, in adult patients with chronic hand eczema. JAK inhibition has been shown to treat a range of inflammatory diseases including hand eczema, and we believe that, due to its demonstrated potency and high selectivity for JAK1 over JAK2, ARQ-252 has the potential to treat hand eczema without causing the adverse effects that may be associated with other less selective JAK inhibitors.

The Phase 1 portion of the study will assess the safety, tolerability and pharmacokinetics of once daily application of ARQ-252 cream 0.3% to both hands for two weeks in six subjects with chronic hand eczema. The Phase 2b portion of the study will assess the safety and efficacy of ARQ-252 cream 0.1% once daily and ARQ-252 cream 0.3% once daily and twice daily versus vehicle applied once daily and twice daily for 12 weeks to patients with chronic hand eczema. The Company expects to begin the Phase 2b portion of the study in the second half of 2020, and expects topline data in the second half of 2021.

About Hand EczemaHand eczema is a common, predominantly inflammatory, skin disease. It is the most common skin disease affecting the hands, with prevalence estimated at up to 2.5% of the population. Hand eczema is characterized variously by redness, fluid filled blisters or bumps, scaling, cracking, itching and pain occurring on the hands, especially the palms. It is a diverse syndrome, incorporating dyshidrotic eczema, an immune disease possibly related to atopic dermatitis; irritant contact dermatitis of the hands, which is caused by occupational irritants such as chemicals; allergic contact dermatitis of the hands, which is caused by an allergic reaction; atopic hand dermatitis, which is atopic dermatitis occurring on the hands, and hyperkeratotic hand dermatitis, which are thickened, scaly, red plaques, similar to psoriasis, on the hands. The impact of hand eczema on patients can be significant, leading to work absences or disability, social stigmatization, and psychosocial distress.

About ARQ-252 ARQ-252 is a potent and highly selective topical, small molecule inhibitor of janus kinase type 1 (JAK1). Many inflammatory cytokines and other signaling molecules rely on the JAK pathway, and specifically JAK1, which plays a central role in immune system function. Inhibition of JAK1 has been shown to treat a range of inflammatory diseases, including rheumatoid arthritis, psoriasis, Crohns disease, and atopic dermatitis. The Company believes that due to its high selectivity for JAK1 over JAK2, ARQ-252 will be able to effectively treat inflammatory diseases without causing the hematopoietic adverse effects typically associated with JAK2 inhibition. In 2018, Arcutis exclusively licensed the active pharmaceutical ingredient in ARQ-252 for all topical dermatological uses in the United States, Europe, Japan and Canada from Jiangsu Hengrui Medicine Co., Ltd. of China. In mid-2019, Hengrui completed a Phase 2 study in rheumatoid arthritis that used the same active pharmaceutical ingredient as in ARQ-252 but dosed orally. The results confirmed that this active pharmaceutical ingredient is a highly potent inhibitor of JAK1 based on the drugs impact on rheumatoid arthritis, and was generally well tolerated at exposures well above those expected with topical administration of ARQ-252.

About Arcutis - Bioscience, applied to the skin.Arcutis is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. Arcutis exploits recent innovations in inflammation and immunology to develop potential best-in-class therapies against validated biological targets, leveraging our deep development, formulation and commercialization expertise to bring to market novel dermatology treatments, while maximizing our probability of technical success and financial resources. Arcutis is currently developing three novel compounds (topical roflumilast cream (ARQ-151), topical roflumilast foam (ARQ-154) and ARQ-252) for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema. For more information, please visit http://www.arcutis.com or follow the Company on LinkedIn.

Story continues

Forward Looking StatementsThis press release contains "forward-looking" statements, including, among others, statements regarding the potential for ARQ-252 to treat hand eczema without causing the adverse effects associated with other JAK inhibitors; the anticipated timing of beginning the Phase 2b portion of the Phase 1/2b study; and the anticipated timing of the topline data of the Phase 2b portion of the study. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the "Risk Factors" section of our Annual Report on Form 10-K filed withU.S. Securities and Exchange Commission(SEC) onMarch 19, 2020, as well as any subsequent filings with theSEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Investors and Media:Heather Rowe ArmstrongVice President, Investor Relations & Corporate Communicationsharmstrong@arcutis.com805-418-5006, Ext. 740

See the rest here:

Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema - Yahoo Finance

The effects of psoriasis can be more than skin deep – PhillyVoice.com

Psoriasis is a common skin condition that causes raised, red, scaly patches of skin that can feel itchy or painful. But if that inflammation can't be kept in check, it can affect a person's entire body.

Psoriasis prompts skin cells to rapidly multiply, causing a buildup of lesions on certain skin surfaces. Many cases are mild, but severe cases can lead to permanent disfigurement and joint disease. About 30% of people with psoriasis willdeveloppsoriatic arthritis,which causes inflammation in the joints and tendons.

The condition's pathology is not really known, according to Dr. Jonathan Wolfe, head of the dermatology division at Einstein Medical Center Montgomery. But the prevailing thought is that it is an immune disorder.

New research suggests that psoriasis is a systemic disease that can affect any part of the body in which inflammation can spread, Wolfe said.

"Triggers of psoriasis include injuries, infection, stress, smoking, heavy alcohol use and certain blood pressure medicines," Wolfe said. "A family history of psoriasis is also a common theme."

Psoriasis increases risk forserious health conditionslike diabetes, obesity, high blood pressure, cardiovascular disease and autoimmune diseases.It also can lead to depression.

Psoriasis comes in various forms, including plaque psoriasis which has telltale thick, silvery scales anderythrodermicpsoriasis, in which most of the body reddens and becomes itchy and painful.

Plaque psoriasis normally develops on the elbows, knees or scalp, but it can appear on any part of the body. It tends to wax and wane at different times. Some people only will develop lesions on just a few skin surfaces while others will have the lesions across their bodies.

Erythrodermic psoriasis is the least common form, but it can result in a medical emergency especially for people with cardiac disease. This severe form of psoriasis can cause swelling from fluid retention and infection, increasing the risk of pneumonia and congestive heart failure.

It can also cause skin on most areas of the body to turn bright red and become itchy and painful. The skin sometimes falls off in sheets. People with unstable plaque psoriasis are most at-risk for developing it.

Other forms include nail psoriasis, which is identifiable by pitting in the nails or abnormal nail discoloration, and guttate psoriasis, which is similar to plaque psoriasis but results in more coin-shaped lesions. The latter form usually appears on the trunk of the body and is triggered by strep or another bacterial infection.

Inverse psoriasis, which occurs in the groin area and underneath the breasts and armpits, often is mistaken for a fungi infection. That can delay a patient from receiving the correct treatment.

Pustular psoriasis develops as white pustules of noninfectious pus that are surrounded by red skin, causing people to feel sick with fever and chills.

Additionally, some patients with psoriasis will develop lesions on areas that are notnormally affected by the condition a development known as the Koebner phenomenon.

Treatment options range from topical medications like corticosteroids, retinoids and vitamin D analogues to oral and injectable medications.

For more severe cases, narrow ultraviolet B phototherapy and photochemotherapy are used. Photochemotherapy requires patients to take light-sensitizing medicine before being exposed to UVB rays.

There also are biologic drugs made from living cells that target specific parts of the immune system, leading to better control of symptoms and better quality of life. They have changed the way psoriasis has been treated in the last 25 years, Wolfe said.

Anyone who develop psoriasis should talk to their doctor as soon as possible. Wolfe said,"If left untreated, psoriasis can make routine things uncomfortable and cause serious complications."

More here:

The effects of psoriasis can be more than skin deep - PhillyVoice.com

Arcutis Announces Data from the Phase 2b Study of Topical Roflumilast Cream in Patients with Plaque Psoriasis Selected for Late-Breaking Oral…

WESTLAKE VILLAGE, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, will showcase data on its investigational program studying topical roflumilast cream (ARQ-151) in patients with chronic plaque psoriasis at the 2020 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO, on March 20-24, 2020.

We are delighted to participate in the scientific exchange at this years AAD meeting, said Howard Welgus, MD, Chief Medical Officer at Arcutis. Patients and dermatologists need new and better topical treatment options that provide improved efficacy, safety and tolerability for patients with plaque psoriasis. We look forward to sharing data that demonstrate how topical roflumilast cream could, if approved, provide a once daily treatment option that effectively addresses the current challenges of treating plaque psoriasis with topical therapies."

Title: ARQ-151, Roflumilast Cream, Significantly Improves Chronic Plaque Psoriasis in Phase 2b StudySession: S027 - Late-breaking Research: Clinical TrialsPresenter: Dr. Linda Stein Gold, Director of Dermatology Clinical Research and Division Head of Dermatology at the Henry Ford Hospital in Detroit, MichiganDate: Saturday, March 21, 9:00 9:10 a.m. MTLocation: Bellco Theatre 2

In addition, results from the Phase 1/2a study of topical roflumilast cream in chronic plaque psoriasis have been accepted for an e-poster presentation.

Title: ARQ-151, Roflumilast Cream, Improved Psoriasis in Phase 2a StudyAbstract/poster number: 15309Date: ePosters will be presented Friday, March 20 - Sunday, March 22, 9 a.m. - 5 p.m. MT

About Topical Roflumilast Cream (ARQ-151)Topical roflumilast cream (ARQ-151) is a topical cream formulation containing roflumilast, a PDE4 inhibitor, that Arcutis is developing to treat plaque psoriasis, including intertriginous psoriasis, and atopic dermatitis. PDE4 is an intracellular enzyme that regulates pro-inflammatory and anti-inflammatory cytokine production and cell proliferation. Roflumilast was approved by the FDA for systemic treatment to reduce risk of exacerbation of chronic obstructive pulmonary disease (COPD) in 2011, and has shown greater potency based on IC50 values (a non-clinical measure of a drug's potency) than other PDE4 inhibitors.

About Arcutis - Bioscience, applied to the skin.Arcutis is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. Arcutis exploits recent innovations in inflammation and immunology to develop potential best-in-class therapies against validated biological targets, leveraging our deep development, formulation and commercialization expertise to bring to market novel dermatology treatments, while maximizing our probability of technical success and financial resources. Arcutis is currently developing three novel compounds (topical roflumilast cream (ARQ-151), topical roflumilast foam (ARQ-154) and ARQ-252) for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema. For more information, please visit http://www.arcutis.com or follow the Company on LinkedIn.

Contact:John W. SmitherChief Financial Officerjsmither@arcutis.com

Investors and Media:Heather Rowe ArmstrongVice President, Investor Relations & Corporate Communicationsharmstrong@arcutis.com805-418-5006, Ext. 740

Read the original here:

Arcutis Announces Data from the Phase 2b Study of Topical Roflumilast Cream in Patients with Plaque Psoriasis Selected for Late-Breaking Oral...